Neurocrine Biosciences, Inc.

Neurocrine Biosciences is a specialty pharma anchored by INGREZZA (valbenazine for tardive dyskinesia and Huntington disease chorea) plus Crenessity (crinecerfont for congenital adrenal hyperplasia) and an expanding pipeline. The stock is up 35% over the past twelve months on continued INGREZZA acceleration and the Crenessity commercial-launch cadence.

Where the setup is:

• Last quarter posted $814 million in revenue up 42% year-on-year with a 98% gross margin and 25% operating margin — real explosive top-line growth combined with striking software-like economics, and free-cash-flow yield sits at 5.2% on the growing base.
• Valuation is reasonable at 23.8x trailing price-to-earnings and 5.13x price-to-sales — the multiple prices in continued INGREZZA and Crenessity growth, and return on invested capital sits at 13.7% on the growing base.
• On July 8 Zacks upgraded Neurocrine to Strong Buy citing INGREZZA guiding to $2.7-$2.8 billion in sales with patent protection through 2038 — real defining sell-side conviction signal, and UBS's Crinetics initiation included Crenessity as the first-entrant congenital adrenal hyperplasia driver toward roughly $750 million in second-year launch sales.
• Insider tape: officer Ingrid Delaet executed exercise-and-sell activity July 7-9 selling roughly 11,170 combined shares at $178.54-$178.72 for roughly $2.0 million.
• Consensus sees $7.72 in earnings per share on $3.73 billion revenue for the current year and $9.82 on $4.35 billion next year — real meaningful earnings-power expansion combined with continued margin discipline.

July 29 Q2 earnings is the confirmation event — INGREZZA prescription trajectory, Crenessity commercial-launch commentary, gross-margin trajectory, pipeline-progression commentary, and any capital-return update decide whether the extended 99%-of-range tape sustains toward the sell-side's forward-year framing.